Keyphrases
Light Chain Amyloidosis
87%
AL Amyloidosis
50%
Immunoglobulin Light Chains
42%
Bortezomib
41%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
41%
Lenalidomide
40%
Daratumumab
40%
Europe
40%
Median Overall Survival
30%
Hematological Response
23%
Multiple Myeloma
22%
Cardiac Involvement
22%
Plasmatic Coagulation
20%
Coagulability
20%
Real-life Cohort
20%
Plasma Cell Leukemia
20%
Clinical Characteristics
20%
Cilta-cel
20%
Brexucabtagene Autoleucel
20%
Efficacy Outcomes
20%
Older Patients
20%
Phase II Study
20%
T-lymphoblastic Lymphoma
20%
Carfilzomib
20%
Treatment Patterns
20%
Immunoglobulin Light Chain Amyloidosis
20%
Intensive Care Unit
20%
Treatment Efficacy
20%
Young Patients
20%
Advanced Disease
20%
Acalculous Cholecystitis
20%
Red Blood Cells
20%
Healthcare Resource Utilization
20%
Cost of Illness
20%
Resource Cost
20%
Diagnostic Performance
20%
Liver Stiffness
20%
Liver Involvement
20%
Maintenance Therapy
17%
Progression-free Survival
17%
Dialysis
16%
Complete Response
15%
Serum Neurofilament Light Chain
15%
Serious Adverse Events
14%
Induction Therapy
14%
Consolidation Therapy
14%
Early Diagnosis
13%
High-dose Melphalan
13%
Overall Survival
13%
Triple-class Exposed
13%
Medicine and Dentistry
Multiple Myeloma
83%
Lenalidomide
60%
Immunoglobulin Light Chain
40%
AL Amyloidosis
40%
Cohort Analysis
40%
Disease
37%
Progression Free Survival
35%
Overall Survival
26%
Adverse Event
25%
CAR T-cell therapy
25%
B Cell Maturation Antigen
25%
T Cell
24%
Bortezomib
24%
Thromboelastography
23%
Blood Stasis
23%
Dexamethasone
23%
Autologous Stem Cell Transplantation
20%
Proteasome Inhibitor
20%
Cauda equina
20%
Lymphoblastic Lymphoma
20%
Plasma Cell Leukemia
20%
Carfilzomib
20%
Erythrocyte
20%
Thrombocytopenia
20%
Intensive Care
20%
Acalculous Cholecystitis
20%
Diagnostic Performance
20%
Daratumumab
20%
Platelet
16%
Cytokine
16%
Care Group
15%
Chimeric Antigen Receptor T-Cell Therapy
13%
Infusion
13%
Chimeric Antigen Receptor T-Cell
12%
Pharmacokinetics
12%
Progressive Disease
10%
Infection
10%
Thrombus
10%
Vascular Disease
10%
Blood Clotting
10%
Diagnosis
10%
Hazard Ratio
10%
Serum Amyloid P
10%
Scintigraphy
10%
Anemia
9%
Symptom
9%
Disease Exacerbation
9%
Melphalan
8%
Neoplasm
8%
Drug Megadose
8%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Myeloma
100%
Disease
73%
AL Amyloidosis
60%
Lenalidomide
60%
Bortezomib
50%
Adverse Event
42%
Cohort Study
40%
Dexamethasone
40%
Daratumumab
40%
Progression Free Survival
33%
Overall Survival
33%
B Cell Maturation Antigen
25%
Proteasome Inhibitor
20%
Immunoglobulin Light Chain
20%
Disease Exacerbation
17%
Cytokine
16%
Minimal Residual Disease
13%
Pharmacokinetics
12%
Monoclonal Antibody
10%
Melphalan
8%
Myeloma
8%
Prospective Study
6%
Observational Study
6%
Heart Disease
6%
Side Effect
5%
Peripheral Neuropathy
5%
Cranial Nerve Paralysis
5%
Toxicity and Intoxication
5%
Open-Label Trial
5%
Epileptic Absence
5%
Cytokine Release Syndrome
5%
Symptom
5%
